Phase 1Completed
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection, for Subcutaneous Use in Combination With Semaglutide in Participants With Obesity
- Sponsor
- Ascletis Pharma (China) Co., Limited (Industry)
- Enrolment
- 28 enrolled
- Conditions
- Chronic Weight Management
- Interventions
- ASC47 +Semaglutide; Placebo+Semaglutide
- Ages
- adults, older adults
- Registry
- NCT06972992
Full record on ClinicalTrials.gov
From the registry
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Primary outcomes
- Adverse events
History
Last registry update
Primary completion
Registered
Started
In the news
ResearchDeutsches Ärzteblatt (opens Deutsches Ärzteblatt in a new tab)
Researchers find weight loss cannot fully explain semaglutide’s 20% cardiovascular risk reduction
The SELECT mediation analysis examined 24-month risk-factor changes in adults with cardiovascular disease, BMI ≥27 and no diabetes, assigned to weekly semaglutide targeting 2.4 mg or placebo.
